Mark Geier David Geier
Geier, MR and Geier, DA
[back] Vaccine critics & studies/sites on vaccine autism link
[back]
Mercury
[back]
Mark Geier
David Geier
"In my view, this is not a scientific issue. This is
about as proven an issue as you’re ever going to see, and what’s occurring
here is a cover up under the guise of protecting the vaccine program. And I’m
for the vaccine program. You keep covering it up and your not going to have a
vaccine program," Geier
[2014] Methodological Issues and Evidence of Malfeasance in Research Purporting
to Show Thimerosal in Vaccines Is Safe. Brian Hooker, Janet Kern, David
Geier, Boyd Haley, Lisa Sykes, Paul King, and Mark Geier
The purpose of this review is to examine these six publications [21–26] which
were “overseen” by the CDC and which claim that prenatal and early childhood
vaccine-derived Thimerosal exposures are not related to the risk of a subsequent
diagnosis of autism or autism spectrum disorder (ASD). This review analyzes
possible reasons why their published outcomes are so different from the results
of investigations by multiple independent research groups over the past 75+
years. The review begins with an examination of the Madsen et al. [21] study.
[2013] Kern, J.K.; Haley, B.E.;
Geier, D.A.; Sykes, L.K.; King, P.G.; Geier, M.R. Thimerosal Exposure
and the Role of Sulfation Chemistry and Thiol Availability in
Autism. Int. J. Environ. Res. Public Health 2013, 10, 3771-3800.
The evidence suggests that the abnormal sulfation chemistry, limited
thiol availability, and decreased GSH reserve capacity could explain why
the adverse effects of TM are greater in a subpopulation of children
with this susceptibility and why the subsequent brain insult is more
pronounced in them, as has been shown repeatedly in the animal model.
Furthermore, it has recently been demonstrated that polymorphisms in
glutathione-related genes modify Hg concentrations and antioxidant
status in human subjects environmentally exposed to Hg [165].
With the rate of children diagnosed with an ASD in the US now
exceeding 1 in 50 children [166] and the rate of children with
neurodevelopmental/behavioral disorders in the US now exceeding 1 in 6
children [167], and the preceding evidence showing that there is
vulnerability to TM that would not be known without extensive testing,
the preponderance of the evidence indicates that TM should be removed
from all vaccines.
[2010 July] The Avalanche of New Mercury-Autism Studies by Mark Geier, MD, PhD & David Geier
[2008] Key realities about autism, vaccines, vaccine-injury compensation, Thimerosal, and autism-related research----Gary S. Goldman, Ph.D & P.G. King PhD.
DA Geier et al, Neurodevelopmental disorders, maternal Rh-negativity, and Rho(D) immune globulins: a multi-center assessment Neuro Endocrinol Lett. 2008 Apr;29(2):272-80 This study associates TCR exposure with some NDs in children
[2007] The Journal of Toxicology and Environmental
Health, Part A: Current Issues, an authoritative journal featuring original
toxicological research, has published, "A Case Series
of Children with Apparent Mercury Toxic Encephalopathies
Manifesting with Clinical Symptoms of Regressive Autistic
Disorders," by Geier and Geier (2007).
This new study leaves little doubt there is a direct causal link between mercury
exposure from Thimerosal-preserved biological products (vaccines and
Rho(D) products) and mercury poisoning diagnosed as an autism spectrum
disorder (ASD).http://www.medicalnewstoday.com/medicalnews.php?newsid=69427
False information in DeStefano/Rhodes response to M. Geier 24 March 2004
[pdf] Geier
D, Geier M. The true story of pertussis vaccination: a
sordid legacy? J Hist Med Allied Sci. 2002
Jul;57(3):249-84.
http://www3.oup.co.uk/jalsci/hdb/Volume_57/Issue_03/pdf/570249.pdf?DID=1721191473605346
Jan 2004 A Review of the Relationship between Thimerosal and Autism.
Geier MR and Geier DA. Gastrointestinal adverse reactions following anthrax vaccination: an analysis of the Vaccine Adverse Events Reporting System (VAERS) database. Hepatogastroenterology. 2004 May-Jun;51(57):762-7.
Geier, MR and Geier, DA, "Thimerosal in Childhood Vaccines, Neurodevelopment Disorders, and Heart Disease in the United States," JAPS, Vol 8(1);Spring 2003:6-10.
Geier DA, Geier MR. A prospective study of Thimerosal-containing Rho(D)-immune globulin administration as a risk factor for autistic disorders. J Maternal-Fetal and Neonatal Med. 2007 May; 20(5):385–90.
Geier DA, Sykes LK, Geier MR.A review of Thimerosal (merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness. J Toxicol Environ Health B Crit Rev. 2007 Dec.; 10(8):575–96.
Thimerosal (Merthiolate) is an ethylmercury-containing pharmaceutical compound that is 49.55% mercury and that was developed in 1927. Thimerosal has been marketed as an antimicrobial agent in a range of products, including topical antiseptic solutions and antiseptic ointments for treating cuts, nasal sprays, eye solutions, vaginal spermicides, diaper rash treatments, and perhaps most importantly as a preservative in vaccines and other injectable biological products, including Rho(D)-immune globulin preparations, despite evidence, dating to the early 1930s, indicating Thimerosal to be potentially hazardous to humans and ineffective as an antimicrobial agent. Despite this, Thimerosal was not scrutinized as part of U.S. pharmaceutical products until the 1980s, when the U.S. Food and Drug Administration finally recognized its demonstrated ineffectiveness and toxicity in topical pharmaceutical products, and began to eliminate it from these. Ironically, while Thimerosal was being eliminated from topicals, it was becoming more and more ubiquitous in the recommended immunization schedule for infants and pregnant women. Furthermore, Thimerosal continues to be administered, as part of mandated immunizations and other pharmaceutical products, in the United States and globally. The ubiquitous and largely unchecked place of Thimerosal in pharmaceuticals, therefore, represents a medical crisis. PMID: 18049924 [PubMed - indexed for MEDLINE]
Geier DA, Geier MR.A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007 May 15; 70(10):837–51.
Geier DA, Geier MR. A prospective study of Thimerosalcontaining Rho(D)-immune globulin administration as a risk factor for autistic disorders. J Matern Fetal Neonatal Med. 2007 May; 20(5):385–90.
Geier DA, Geier MR.A case series of children with apparent mercury toxic encephalopathies manifesting with clinical symptoms of regressive autistic disorders. J Toxicol Environ Health A. 2007 May 15; 70(10):837–51.
Geier DA, Geier MR. A meta-analysis epidemiological assessment of neurodevelopmental disorders following vaccines administered from 1994 through 2000 in the United States. Neuro Endocrinol Lett. 2006 Aug.; 27(4) 401–13.
Geier DA, Geier MR. An evaluation of the effects of Thimerosal on neurodevelopmental disorders reported following DTP and Hib vaccines in comparison to DTPH vaccine in the United States. J Toxicol Environ Health A. 2006 Aug.; 69(15):1481–95.
Geier DA, Geier MR.A two-phased population epidemiological study of the safety of Thimerosal-containing vaccines: a followup analysis. Med Sci Monit. 2005 April; 11(4):CR160–70. Epub 2005 Mar 24.
David A Geier,
Mark R Geier MD PhD.
Chronic adverse reactions associated with hepatitis B vaccination.
The Annals of Pharmacotherapy 2002: Vol. 36,
No. 12, pp. 1970–1971.
In conclusion, our study demonstrates that
adult HBV is statistically associated not only
with acute neuropathy, neuritis, myelitis, vasculitis, thrombocytopenia,
gastrointestinal disease, multiple sclerosis, and arthritis, but some of these
patients go on to develop chronic adverse reactions that persist for at least 1
year following HBV. These types of chronic adverse reactions following
adult HBV should be discussed with patients contemplating being immunized with
HBV and should be included in the differential diagnosis of those who develop
them following adult HBV.
Geier DA, Geier MR.
A one year follow up of chronic arthritis following rubella and hepatitis B
vaccination based upon analysis of the Vaccine Adverse Events Reporting System
(VAERS) database. Clin Exp Rheumatol
2002 Nov-Dec;20(6):767-71. MedCon, Inc.,
Silver Spring, Maryland, USA.
mgeier@erols.com
OBJECTIVES: This analysis examined the incidence rate of chronic arthritis
adverse reactions reported following adult rubella and hepatitis B
vaccinations. In this analysis, etiologic mechanisms for chronic arthritis
following adult rubella and hepatitis B vaccines were also explored. METHODS:
The Vaccine Adverse Events Reporting System (VAERS) database was analyzed for
the incidence rate of reported cases of chronic arthritis in comparison to
Tetanus-diphtheria (Td) and tetanus toxoid adult vaccine control groups.
RESULTS: Chronic arthritis adverse reactions following adult rubella
vaccination were primarily reported in females (female/male ratio = 3.0), at
about 45 years-old, and at a mean onset time of 10-11 days following
vaccination. Chronic arthritis adverse reactions following adult hepatitis B
vaccination were also primarily reported in females(female/male ratio = 3.5),
at about 33 years-old, and with a mean onset time of 16 days following
vaccination. The incidence rates of chronic arthritis following adult rubella
and adult hepatitis B vaccinations were statistically significantly increased,
by chi 2 analysis, in comparison to the adult vaccine control groups. The
attributable risk of chronic arthritis following adult rubella vaccine ranged
from 32 to 53 and from 5.1 to 9.0 following adult hepatitis B vaccine in
comparison to the adult vaccine control groups. CONCLUSION: This study
revealed that adult rubella and adult hepatitis B vaccines were statistically
associated with chronic arthritis which persisted for at least one year.
The etiology for these adverse reactions may involve autoimmune mechanisms.
Furthermore, potential biases in the reporting rates of adverse reactions to
VAERS were not observed. PMID: 12508767
[PubMed - in process]
"A Meta-Analysis Study (VAERS Database)"
"An Assessment of Downward Trends Following Thimerosal Removal (VAERS Database - Ecological Study"
"An Evaluation of the Effects of Thimerosal on Neurodevelopmental Disorders (VAERS Database)"
"Neurodevelopmental Disorders Following TCVs - A Follow-up Analysis (VAERS Database)
"A Case-Control Study of Mercury Burden in Children with Autistic Spectrum Disorders"
"A Case-Series of Children with Mercury Toxic Encephalopathies"
"Published Hormone Research Article 2006"
"Published Mercury and Testosterone Medical Hypothesis"
"Evolving views on the causes of autistic spectrum disorders"
"Thimerosal Does Not Belong in Vaccines"
"Study Misses Link Between Thimerosal and Neurodevelopmental Disorders"
"Geier and Geier Lancet Published Letter"
"Parents Fears About Thimerosal"
"Response to Comments by JR Mann"
